Incyte Corporation vs Cloudflare Inc — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Cloudflare Inc trades at $360.65 (market cap $121.74B). The key difference: Cloudflare Inc is far larger — about 5.3× Incyte Corporation's market cap, and Cloudflare Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Cloudflare Inc for 61 Days on average.
| INCY | NET | |
|---|---|---|
Market Cap | $22.85B | $121.74B |
Volume | 1,927,029 | 2,433,002 |
Sector | Health | Technology |
52-Week High | $129.93 | $359.60 |
52-Week Low | $83.80 | $160.16 |
Typical Hold Time | 33 Days | 61 Days |
Enterprise Value | $18.35B | $121.11B |
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Cloudflare (NET) trades at $361.00, up 5.3% in the last session, with strong technical momentum and bullish moving average signals. The company shows robust revenue growth, reaching $2.17B in 2025, but remains unprofitable with a net margin of -8.21%. Recent product launches like Cloudflare Basin and strategic partnerships with Deutsche Telekom highlight innovation, while analyst consensus is strongly bullish with 71% buy ratings and a $328.71 price target.
Outlook: Growth prospects are solid with accelerating revenue and enterprise adoption, but high valuation multiples (P/S 47.88) and persistent losses pose risks. Investors should weigh the company's market leadership against profitability challenges and competitive pressures in the edge cloud space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →